GSL: General Sales Licence
This information is intended for use by health professionals
Boots Dermacare Itch Relief Cream
Active ingredient: Crotamiton 10%.
For excipients see 6.1.
A white to cream coloured cream, with a slight characteristic odour.
For the relief of itching and skin irritation caused by, for example, sunburn, dry eczema, itchy dermatitis, allergic rashes, hives, nettle rash, chickenpox, insect bites and stings, heat rashes and personal itching.
The treatment of scabies.
Adults (including the elderly):
Apply to the affected area 2-3 times daily. Eurax/ Boots Dermacare Itch Relief Cream will provide relief from irritation for 6 to10 hours after each application. There are no special dosage recommendations in the elderly.
Eurax/ Boots Dermacare Itch Relief Cream can be used in children. However for children under three years of age, usage should only be used under medical supervision and it should not be applied more than once a day.
Adults (including the elderly):
After the patient has taken a warm bath, the skin should be well dried and Eurax/ Boots Dermacare Itch Relief Cream rubbed into the entire body surface (excluding the face and scalp) until no traces of the preparation remain visible on the surface. The application should be repeated once daily, preferably in the evening, for a total of 3-5 days. Depending on the response, special attention should be paid to sites that are particularly susceptible to infestation by the mites (eg interdigital spaces, wrists, axillae and genitalia). Areas where there is pus formation should be covered with a dressing impregnated with Eurax/ Boots Dermacare Itch Relief Cream. While the treatment is in progress the patient may take a bath shortly before the next application. After completion of the treatment, a cleansing bath should be taken followed by a change of bed linen and underclothing.
There are no special dosage recommendations in the elderly.
Eurax/Boots Dermacare Itch Relief Cream can be used in children. For children under three years of age consult a doctor before use and do not apply more than once a day.
Method of administration: For cutaneous use.
Acute exudative dermatoses. Hypersensitivity to the active substance or to any of the excipients (see section 6.1, List of excipients).
For external use only.
Eurax/ Boots Dermacare Itch Relief Cream can be used for children; However for children under three years of age usage should only be under medical supervision.
Should not be used in buccal mucosa and in or around the eyes since contact with the eyelids may give rise to conjunctival inflammation. In case of accidental contact with the eyes, or buccal mucosa rinse thoroughly with running water.
Should not be applied in the presence of exudative wounds, acute eczema, broken skin, or very inflamed skin. In the presence of eczematous scabies, eczema should be treated before the scabies.
Eurax/ Boots Dermacare Itch Relief cream contains stearyl alcohol which may cause local skin reactions (e.g. contact dermatitis) and methyl hydroxybenzoate which may cause allergic reactions (possibly delayed).
Eurax/ Boots Dermacare Itch Relief cream should only be used in pregnancy, breast feeding or for genital itching under medical supervision.
No interaction studies have been performed.
There are no controlled studies of Eurax/Boots Dermacare Itch Relief Cream in human pregnancy. Therefore Eurax/Boots Dermacare Itch Relief Cream is not recommended during pregnancy, especially in the first three months.
It is not known whether the active substance of Eurax/Boots Dermacare Itch Relief Cream passes into breast milk after topical administration. Therefore mothers should not use Eurax/Boots Dermacare Itch Relief Cream whilst breastfeeding unless directed by a physician. If Eurax/Boots Dermacare Itch Relief Cream is used during breastfeeding it should not be applied to the nipple area.
No data is available on the potential effects of crotamiton on fertility.
Eurax/Boots Dermacare Itch Relief Cream has no influence on the ability to drive and use machines.
Summary of the safety profile
The most commonly reported adverse reaction during treatment is pruritus. Contact dermatitis and hypersensitivity reactions like rash, eczema, erythema, skin irritation and angioedema may occur rarely.
Tabulated list of adverse reactions
Adverse reactions are listed below by system organ class and frequency. Frequencies are defined as: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000), or not known (can not to be estimated from available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
System Organ Class (SOC)
Skin and subcutaneous tissue disorders
Contact dermatitis, hypersensitivity (like rash, eczema, erythema, skin irritation, angioedema)
Treatment should be discontinued if severe irritation occurs.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yel1owcard.
In cases of accidental ingestion, acute intoxication symptoms may be observed such as nausea, vomiting and irritation of the buccal, oesophageal and gastric mucosa. Rare cases of loss of consciousness and seizure were reported. General measures to eliminate the drug and reduce its absorption should be undertaken.
Symptomatic treatment should be administered as appropriate. Moreover although very rare, risk of methaemoglobinaemia exists in case of accidental ingestion as well as in case of excessive cutaneous absorption. The symptoms usually disappear following the discontinuation of the drug, but in severe cases treatment with methylene blue may be considered.
Pharmacotherapeutic group: other antipruritics (ATC code D04AX) and other ectoparasiticides, including scabicides (ATC code P03AX).
Crotamiton has a symptomatic action on pruritus and is an acaricide. As an acaricide agent, crotamiton is effective on the motor system of the mites by inducing irreversible cessation of spontaneous movements.
Eurax/Boots Dermacare Itch Relief Cream will provide relief from irritation for 6 to 10 hours after each application.
Eurax penetrates rapidly into human skin. Low but measurable concentrations of crotamiton are found in plasma, with a maximum level after 4-10 hours, declining rapidly thereafter.
No preclinical studies were performed using Eurax Cream. Preclinical data do not show teratogenic nor genotoxic risk for crotamiton. Abnormalities of foetal development were observed following administration of corticosteroids to pregnant animals. Eurax Cream, a crotamiton containing cream, administered topically once daily for 3 months to rabbits was tolerated at doses of up to 200 mg/kg without signs of toxicity, apart from transient skin irritation. No sensitising or photo-sensitising potential has been observed in animal studies.
Sodium lauryl sulphate
Ethylene glycol monostearate
Strong ammonia solution 25%
Perfume Givaudan No 45
Do not store above 25°C.
Internally lacquered aluminium tube with an inner coating made of epoxy-phenol resin lacquer closed with a polyethylene screw cap, in a cardboard carton.
Pack sizes: 20, 30 and 100g
GlaxoSmithKline Consumer Healthcare (UK) Trading Limited,
980 Great West Road
980 Great West Road, Brentford, Middlesex, TW8 9GS
0800 783 8881
0800 783 8881